PRAM1 Polyklonale Antilichaam

Complete remission of acute promyelocytic leukemia can be achieved by treating patients with retinoic acid, and PML-RAR-a (promyelocytic leukemia-retinoic acid receptor alpha fusion protein) plays a major role in mediating retinoic acid effects in leukemia cells. The retinoic acid-induced gene, PRAM-1 (PML-RAR-a target gene encoding an adaptor molecule 1) encodes an adaptor protein which is expressed and modulated during normal human myelopoiesis. PRAM-1 expression is hindered by expression of PML-RAR-a. The 718 amino acid PRAM-1 protein contains eight N-terminal proline-rich repeats and several proline residues that are clustered as type I or type II SH3 recognition motifs. PRAM-1 demonstrates expression in hematopoietic tissues and lung.

PML RAR; PML RARA regulated adaptor molecule 1; PML RARA target gene encoding an Adaptor Molecule 1; PML-RARA-regulated adapter molecule 1; PRAM 1; PRAM; PRAM-1; PRAM_HUMAN; PRAM1.

Cell membrane

Human

551-650/718

PRAM1

Unconjugated

KLH conjugated synthetic peptide derived from human PRAM1

ELISA, IHC-P, IHC-F, IF (IHC-P), IF (IHC-F), IF (ICC)

Purified by Protein A.

1µg/µl

ELISA (1:500-1000), IHC-P (1:200-400), IHC-F (1:100-500), IF (IHC-P) (1:50-200), IF (IHC-F) (1:50-200), IF (ICC) (1:50-200)

0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Unmodified

Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles.

Mouse, Rat, Dog, Cow, Sheep, Pig, Horse